知镜 Cognispect · 医学文献与研究工作台

Atopic Dermatitis Flare Following Initiation of Nemolizumab.

Burke OM, Beer J, Elman SA.
Journal of drugs in dermatology : JDD · 2026-08-01 · PMID 42555068

文献摘要

Background Atopic dermatitis (AD) is a chronic inflammatory skin disorder marked by intense pruritus and episodic flares. While nemolizumab, an interleukin-31 (IL-31) inhibitor, has demonstrated efficacy in reducing itch severity, its broader effects on skin inflammation are not fully understood. Case presentation We describe a 49-year-old male with longstanding, treatment-resistant AD who began off-label therapy with nemolizumab. Within weeks of initiation, he developed a new pruritic vesiculobullous eruption localized to the palms, clinically and histologically consistent with dyshidrotic eczema. His prior AD lesions remained stable, but the new eruption prompted temporary discontinuation of nemolizumab. Intervention and outcome The patient was treated with intravenous corticosteroids, resulting in significant improvement of the dyshidrotic eczema. Conclusion This case highlights the potential for nemolizumab to exacerbate AD in some patients, emphasizing the need for caution and further research on its inflammatory effects and safety in real-world settings.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。